Q3 2020 13F Holders as of 9/30/2020
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
27.8M
-
Number of holders
-
166
-
Total 13F shares, excl. options
-
18.8M
-
Shares change
-
+608K
-
Total reported value, excl. options
-
$859M
-
Value change
-
+$27.2M
-
Number of buys
-
88
-
Number of sells
-
-75
-
Price
-
$45.78
Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q3 2020
191 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share as of Q3 2020.
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) has 166 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18.8M shares
of 27.8M outstanding shares and own 67.55% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.22M shares), FARALLON CAPITAL MANAGEMENT LLC (1.78M shares), VANGUARD GROUP INC (1.72M shares), RENAISSANCE TECHNOLOGIES LLC (1.03M shares), PRICE T ROWE ASSOCIATES INC /MD/ (974K shares), STATE STREET CORP (964K shares), Krensavage Asset Management, LLC (825K shares), DIMENSIONAL FUND ADVISORS LP (700K shares), AMERIPRISE FINANCIAL INC (608K shares), and Invesco Ltd. (535K shares).
This table shows the top 166 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.